SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

AstraZeneca Pharma India receives notice of termination from AstraZeneca UK

24 Aug 2016 Evaluate

AstraZeneca Pharma India has received a notice of termination from AstraZeneca UK, conveying its decision for termination of distribution arrangements for Meronem in India. This is as a result of a global agreement by AstraZeneca PLC to sell the development and commercialization rights to Pfizer Inc, of its late-stage small molecule antibiotics business.

Meronem is a carbapenem anti-bacterial used for the treatment of serious infections in hospitalized patients. The transaction reinforces AstraZeneca’s focus on developing transformational medicines in its three main therapy areas viz., Cardiovascular and Metabolic Diseases, Respiratory and Oncology, while realizing value from the strong portfolio of established and late-stage antibiotics programs through Pfizer’s dedicated development and commercialization capabilities.

The current distribution arrangements for Meronem in India will terminate in six months from August 24, 2016.

AstraZeneca Pharma India is a global biopharmaceutical company. The company is engaged in the discovery, development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease. The company operates through two segments Healthcare and Clinical Trial.


Astrazeneca Pharma I Share Price

8602.00 82.20 (0.96%)
21-Apr-2026 13:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1670.60
Dr. Reddys Lab 1220.90
Cipla 1231.05
Zydus Lifesciences 927.40
Lupin 2324.30
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×